Sunmax Biotechnology Co., Ltd. (TPEX: 4728)

Market Cap	15.00B
Revenue (ttm)	1.74B
Net Income (ttm)	698.95M
Shares Out	54.46M
EPS (ttm)	12.82
PE Ratio	21.49
Forward PE	n/a
Dividend	11.00 (3.96%)
Ex-Dividend Date	Jul 17, 2024

Volume	2,000
Open	275.50
Previous Close	275.50
Day's Range	275.50 - 276.00
52-Week Range	191.50 - 350.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About Sunmax Biotechnology

Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets collagen-based medical devices in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax FACIALGAIN collagen implant with lidocaine, Sunmax collagen implant I-Plus, Sumax collagen implant I, Sunmax FACIALGAIN collagen implant 1-Plus with lidocaine for the correction of facial defects, such as the fill up of wrinkles; and Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes. It ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4728

Financial Performance

In 2023, Sunmax Biotechnology's revenue was 1.69 billion, an increase of 20.64% compared to the previous year's 1.40 billion. Earnings were 625.71 million, an increase of 17.21%.